肝硬化门静脉血栓分类及形成机制研究进展*

doi:10.3969/j.issn.1672-5069.2025.02.001

摘要/Abstract

Key words: Liver cirrhosis, Portal vein thrombosis, Classification, Mechanism of formation, Risk factors

崔冶齐, 张世斌. 肝硬化门静脉血栓分类及形成机制研究进展^*[J]. 实用肝脏病杂志, 2025, 28(2): 161-164.

Cui Yeqi, Zhang Shibin. Classification and formation mechanism of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2025, 28(2): 161-164.

[1] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology, 2015, 61(2): 660-7.
[2] Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol, 2013, 108(4): 568-574.
[3] Stieber AC, Zetti G, Todo S, et al. The spectrum of portal vein thrombosis in liver transplantation. Ann Surg, 1991, 213(3): 199-206.
[4] Nonami T, Yokoyama I, Iwatsuki S, et al. The incidence of portal vein thrombosis at liver transplantation. Hepatology, 1992, 16(5): 1195-1198.
[5] Gayowski TJ, Marino IR, Doyle HR, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res, 1996, 60(2): 333-338.
[6] Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation, 2000, 69(9): 1873-1881.
[7] Jamieson NV. Changing perspectives in portal vein thrombosis and liver transplantation. Transplantation, 2000, 69(9): 1772-1774.
[8] Bauer J, Johnson S, Durham J, et al. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl, 2006, 12(10): 1544-1551.
[9] Ma J, Yan Z, Luo J, et al. Rational classification of portal vein thrombosis and its clinical significance. PLoS One, 2014, 9(11): e112501.
[10] De Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63(3): 743-752.
[11] Sarin SK, Philips CA, Kamath PS, et al. Toward a Comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology, 2016, 151(4): 574-577,e3.
[12] 任书瑶, 张博静, 韩国宏. 门静脉高压 Baveno Ⅵ共识:门静脉高压的危险分层及个体化治疗. 中华消化杂志, 2015, 35: 5.
[13] 孙鑫, 刘成海. 肝硬化门静脉高压诊治Baveno Ⅶ共识解读——内科视角. 中国中西医结合消化杂志, 2023, 31: 79-84.
[14] 张国, 王文娟. 《肝硬化门静脉血栓管理专家共识》解读. 中国临床新医学, 2021, 14: 740-744.
[15] Anton A, Campreciós G, Pérez-Campuzano V, et al. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow's triad. J Clin Med, 2022, 11(3): 800.
[16] Saad WE. Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy. Semin Intervent Radiol, 2014, 31(3): 262-265.
[17] Odriozola A, Puente Á, Cuadrado A, et al. Portal vein thrombosis in the setting of cirrhosis: A comprehensive review. J Clin Med, 2022, 11(21): 6435.
[18] Sacchetti S, Puricelli C, Mennuni M, et al. Research into new molecular mechanisms in thrombotic diseases paves the way for innovative therapeutic approaches. Int J Mol Sci, 2024, 25(5): 2523.
[19] Driever EG, Von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology, 2022, 75(4): 898-911.
[20] Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood, 2010, 116(6): 878-885.
[21] Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic alterations in patients with cirrhosis: From primary hemostasis to fibrinolysis. Hepatology, 2020, 71(6): 2135-2148.
[22] Turco L, De Raucourt E, Valla DC, et al. Anticoagulation in the cirrhotic patient. JHEP Rep, 2019, 1(3): 227-239.
[23] 薛春燕, 饶晨怡, 吴玲, 等. 肝硬化静脉曲张出血患者门静脉血栓的临床特征. 中国临床医学, 2023, 30: 454-459.
[24] Scheiner B, Balcar L, Nussbaumer RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol, 2022, 76(5): 1090-1099.
[25] Giuli L, Pallozzi M, Venturini G, et al. Molecular mechanisms underlying vascular liver diseases: Focus on thrombosis. Int J Mol Sci, 2023, 24(16): 12754.
[26] Ventura P, Venturelli G, Marcacci M, et al. Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. Thromb Res, 2016, 141: 189-195.
[27] Senzolo M, T MS, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int, 2012, 32(6): 919-927.
[28] Cagin YF, Bilgic Y, Berber İ, et al. The risk factors of portal vein thrombosis in patients with liver cirrhosis. Exp Ther Med, 2019, 17(4): 3189-3194.
[29] Tremblay D, Naymagon L, Troy K, et al. The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis. Blood Coagul Fibrinolysis, 2020, 31(3): 213-218.
[30] Fortea JI, Carrera IG, Puente Á, et al. Portal thrombosis in cirrhosis: Role of thrombophilic disorders. J Clin Med, 2020, 9(9): 2822.
[31] Gaballa D, Bezinover D, Kadry Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: The portal vein thrombosis risk index. Liver Transpl, 2019, 25(12): 1747-1755.
[32] Von Köckritz L, De Gottardi A, Trebicka J, et al. Portal vein thrombosis in patients with cirrhosis. Gastroenterol Rep (Oxf), 2017, 5(2): 148-156.
[33] Yan Y, Xiong Z, Wang X, et al. A novel potential mechanism for the development of portal vein thrombosis in cirrhosis based on portal hemodynamics. Insights Imaging, 2022, 13(1): 192.
[34] Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 435-446.
[35] Dai CY, Chuang WL, Yu ML. Predicting portal thrombosis in cirrhosis: Some issues. J Hepatol, 2022, 76(1): 224-225.
[36] Li J, Wang Q, Yang M, et al. Metabolic Disorders and risk of portal vein thrombosis in liver cirrhosis: A systematic review and Meta-analysis. Turk J Gastroenterol, 2022, 33(7): 541-553.
[37] Lopez-Gomez M, Llop E, Puente A, et al. Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. Hepatol Res, 2021, 51(10): 1064-1072.
[38] Ohlendorf J, Kiene H, Wiegandt J, et al. The impact of thrombophilic factors on disease progression in children with biliary atresia-A single-centre cohort study. J Clin Med, 2023, 12(6): 2108.
[39] Quan X, Ye X, Qian S, et al. Portal vein thrombosis associates with high platelet-fibrin clot strength and platelet activation in decompensated cirrhosis: A retrospective study. Dig Liver Dis, 2023, 55(5): 629-636.
[40] Violi F, Pignatelli P, Castellani V, et al. Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis. Blood Rev, 2023, 57: 100998.
[41] Nicoară-Farcău O, Soy G, Magaz M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis. Semin Thromb Hemost, 2020, 46(6): 673-681.
[42] Wang L, Guo X, Shao X, et al. Association of endoscopic variceal treatment with portal venous system thrombosis in liver cirrhosis: a case-control study. Therap Adv Gastroenterol, 2022, 15: 17562848221087536.
[43] Wang L, Guo X, Xu X, et al. Association of portal venous system thrombosis with endoscopic variceal treatment: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2021, 32(2): 125-131.
[44] Politoske D, Ralls P, Korula J. Portal vein thrombosis following endoscopic variceal sclerotherapy. Prospective controlled comparison in patients with cirrhosis. Dig Dis Sci, 1996, 41(1): 185-190.

肝硬化门静脉血栓分类及形成机制研究进展^*

Classification and formation mechanism of portal vein thrombosis in patients with liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕天富, 南琼. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症患者抗凝治疗研究进展[J]. 实用肝脏病杂志, 2025, 28(2): 165-168.
[2]	何晓非, 陈杰, 赵斌, 陆世峰. 选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 238-241.
[3]	拾倩, 李莉, 倪昊天. 替诺福韦联合安络化纤丸治疗乙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 242-245.
[4]	刘成环, 刘刚, 甘郑宁, 尹桂秀, 李伟霞. 磁共振FRFSE联合多模态影像学技术评估脾脏Gamna-Gandy小体预测乙型肝炎肝硬化患者并发食管胃底静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 246-249.
[5]	田瑞渊, 魏超, 李勇. 益气活血通络方干预对门静脉血栓形成大鼠门静脉再通的影响研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 24-27.
[6]	王宝林, 杜潘艳, 李小超, 侯斌. 自身免疫性肝病患者外周血CD34⁺细胞和血清白细胞介素-3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 64-67.
[7]	郭珍, 王欣, 牛攀霞. 血清HBsAg阳性的肺结核患者抗痨治疗引起病毒再激活和药物性肝损伤发生影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 68-71.
[8]	孙敏, 张倩, 徐刚, 王加林, 何振文. ACLF患者肺部感染发生率及预测因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 84-87.
[9]	沈莉莉, 赵琳, 石磊. 失代偿期乙型肝炎肝硬化并发自发性细菌性腹膜炎患者第三代头孢菌素类耐药情况调查^*[J]. 实用肝脏病杂志, 2025, 28(1): 88-91.
[10]	杨慧玲, 赵文哲, 杨柳青, 杨健, 刘小静. DCE-MRI功能参数诊断代偿期和失代偿期乙型肝炎肝硬化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 92-95.
[11]	叶鹏, 杨本场, 茅明. 恩替卡韦治疗代偿期乙型肝炎肝硬化初治患者远期组织学改善研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 96-99.
[12]	司同, 朱家宝, 吴彬彬. 超声联合剪切波弹性成像评估肝硬化门脉高压症患者并发高风险食管静脉曲张价值分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 100-103.
[13]	朱瑞农, 宋丽群, 钱佶. 生长抑素联合内镜下治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 104-107.
[14]	卓宇宏, 陈平湖, 陈鸿程, 周思君, 陈小云, 范微微, 叶石才. 内镜下套扎术联合生长抑素治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 108-111.
[15]	王旭丽, 蔡明月, 周志明, 陈苏闽. 不同Child-Pugh分级的乙型肝炎肝硬化患者肝脏体积差异分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 112-115.